💸 The Tape

Innovative Industrial Properties, Inc. (NYSE: IIPR) reported a quarter in which net income attributable to common stockholders jumped 62% to $40.7 million, or $1.36 per share — and almost none of that came from being a cannabis REIT.

Total revenues were $63.3 million, up 0.7% from $62.9 million a year ago. That's the number to sit with. New leases and contractual rent escalations were, in the company's own accounting, substantially offset by property sales, tenant defaults and lease terminations. The core rental business is treading water.

What moved the needle was everything else. Interest and other income rose $9.2 million to $10.8 million, driven primarily by $8.5 million of interest and dividend income from the IQHQ investment plus interest on the seller-financed note from the Perth, New York sale. AFFO reached $53.0 million, or $1.83 per share, up from $1.71. Normalized FFO hit $1.70 per share against $1.60.

Strip out IQHQ and the story is considerably less exciting.

The IQHQ pivot, now fully funded

As of June 30, IIP has fully funded $270.0 million into IQHQ, Inc. — a $100.0 million revolving credit facility and $170.0 million of Series G preferred equity, with $120.0 million of that preferred funded during the quarter alone.

IQHQ is a life sciences real estate developer. It is not a cannabis company. Which makes this the largest capital deployment in IIP's recent history, directed entirely outside the sector the company was built to serve.

Executive Chairman Alan Gold framed the quarter around execution across multiple fronts, substantial liquidity and conservative leverage. All accurate. But read the segment math and the strategic message is plainer: with cannabis tenants defaulting and cannabis rents flat, IIP is deploying capital where it can actually underwrite the credit.

The tenant problem, quantified

This is where the release earns points for transparency.

Payments from defaulted tenants have been declining sharply. PharmaCann contributed $3.2 million in Q1 ($0.11/share), then $1.2 million in Q2 ($0.04/share), and just $81,000 quarter-to-date in Q3. 4Front paid $225,000, then $675,000, then $400,000. Total defaulted-tenant payments fell from $3.5 million in Q1 to $1.9 million in Q2 to $481,000 so far in Q3.

That's roughly $0.11 per share of quarterly earnings support evaporating over two quarters. Whatever Q3 looks like, it won't have this cushion.

The underlying resolutions are progressing, at least. IIP has settled all pending litigation with PharmaCann, securing monetary judgments across the New York, Ohio and Pennsylvania leases. Ohio courts released $0.6 million and Pennsylvania $0.3 million of previously escrowed rent. PharmaCann surrendered the Ohio premises in April, and IIP immediately re-leased the 58,000 square foot building to Curaleaf — a quick turn on a distressed asset, and the best operational news in the release.

New York and Pennsylvania are murkier. PharmaCann remains in possession past the surrender dates with IIP's consent, cooperating on license transfers to new tenants. Translation: the licenses are the asset, and moving them takes time.

On 4Front, IIP has tentative arrangements with prospective new tenants for all four assets — a 250,000 sq ft Illinois property, 114,000 sq ft in Washington, and two Massachusetts assets totaling 124,000 sq ft. Each remains subject to licensing transfer approvals and won't take effect until receivership proceedings conclude, anticipated by year-end 2026 or early 2027.

Also worth flagging: IIP applied $1.2 million of security deposits toward rent owed by Battle Green and The Cannabist Company this quarter, against just $18,000 in the prior-year period. Security deposits are a finite resource. Burning them to cover rent is a leading indicator, not a solution.

The balance sheet did real work

Whatever you think of the strategy, the capital markets execution was genuinely impressive.

IIP fully repaid $291 million of 5.50% Unsecured Senior Notes due 2026 and replaced them with an upsized $402.5 million private offering of 6.0% exchangeable senior notes due 2029. It also layered on a stack of secured term loans — $20.0 million at 9.0%, $56.5 million at SOFR+500, four loans totaling $44.9 million at 6.67%, a $7.3 million loan at 7.50%, and a $20.0 million 10.0% loan already repaid in full.

Those rates deserve a second look. 9.0% and SOFR+500 is not investment-grade pricing. IIP is demonstrating access to capital, which matters — but it's paying for the privilege.

Meanwhile the company was busy on both sides of its own stock: issuing 680,842 common shares for $34.8 million and 948,034 preferred shares for $20.9 million through ATM programs, while repurchasing 1,468,542 common shares for $89.0 million at roughly $60.58 — $80.5 million of it funded directly from the exchangeable notes. Issuing equity at the ATM while buying back stock with borrowed money is a defensible arbitrage if you believe the shares are cheap. It is also, unavoidably, a company financing buybacks with 6% debt.

The leverage picture remains genuinely conservative: 14.2% net debt to total gross assets, $3.0 billion in total gross assets, 1.7x net debt to adjusted EBITDA, and $299.7 million in total liquidity.

Dispositions and the dividend

Two property sales, two very different outcomes. Perth, New York sold for $88.5 million under a tenant purchase option, generating a $16.7 million gain — with IIP providing $49.0 million of seller financing, which is how the buyer got there. A San Marcos, Texas land parcel went for $3.3 million at a $4.9 million loss.

The Board declared a $1.90 quarterly dividend — $7.60 annualized — with cumulative distributions since inception now exceeding $1.2 billion. Against $1.83 of AFFO, that's a payout above 100% for the quarter. Sustainable if IQHQ income keeps compounding. Less so if it doesn't and the default payments keep shrinking.

The read

IIP is executing well on a portfolio it would rather not be so concentrated in. Flat cannabis revenue, evaporating default payments, security deposits covering rent, and a $270 million bet on life sciences real estate tell a coherent story: the landlord is diversifying away from its tenants.

The balance sheet buys plenty of time to do it. The question is whether shareholders signed up for a cannabis REIT or a diversified credit investor that happens to own grow facilities.

📈 Dog Walkers

$HELP ( ▲ 3.07% ) Brings In The Big Guns

Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) named Michael Halstead Chief Executive Officer effective immediately — and the timing is not subtle. The clinical-stage company developing novel serotonergic agonists is weeks from topline data on APPROACH, the first pivotal Phase 3 study of HLP003 as an adjunctive treatment for major depressive disorder, expected in Q4 2026.

Halstead's résumé reads like a specification sheet for exactly this moment. He spent his most recent tenure as President of Intra-Cellular Therapies, where he helped convert an early-stage clinical outfit into a fully integrated commercial biopharma — including the development, launch and commercialization of CAPLYTA®, approved across schizophrenia, bipolar depression and, notably, adjunctive MDD. That's the same indication HLP003 is chasing. He also managed multiple equity offerings and led the company's US$14.6 billion sale to Johnson & Johnson in 2025.

Before that: senior roles at Warner Chilcott, where he oversaw the US$3 billion acquisition of Procter & Gamble's pharmaceutical business and the integration of roughly 2,000 employees, then the company's US$8.5 billion sale to Actavis.

The rest of the pipeline continues around him. Enrollment is ongoing in EMBRACE, the second pivotal study in the Phase 3 PARADIGM program, with rollover into the EXTEND long-term extension. HLP004, a short-acting compound for generalized anxiety disorder, sits behind it. Halstead flagged an IP position of 350+ patent applications and 100+ granted patents worldwide.

Hiring a commercialization operator with two multibillion-dollar exits, right before a pivotal readout, tells you what the board is planning for.

📺 Trade To Black

The Hemp Industry Is Front & Center While MSOs Await Rescheduling Fate | TTB Presented by Flowhub

• Texas pulled the plug on July 31. Delta-8, delta-10 and THCP are now controlled substances statewide after the Texas Supreme Court dissolved a five-year-old injunction — erasing roughly a $500 million market and exposing retailers to fines up to $25,000 per violation.

• The CR "lifeline" buys 29 days, not a win. Senate appropriators moved the federal hemp THC ban from November 12 to December 11, but the House passed its own CR without the language — and synthetic cannabinoids get recriminalized on schedule regardless. Michael Bronstein of ATACH explains why the industry is celebrating too early.

• Todd Blanche won't say where he stands. The acting attorney general who signed the April 23 Schedule III order is now Trump's nominee for permanent AG — and just declined to tell Senate Judiciary whether he supports rescheduling adult-use cannabis or easing enforcement penalties.

• Plus: what the expedited DEA hearing means for full Schedule III — and how state-level hemp crackdowns are quietly pushing consumers back into licensed dispensaries.